Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 24, Issue 4, 2011, Pages 191-199

  Stass, Heino ^a   Corkery, Kevin ^b   Gribben, Dennis ^c   Eldon, Michael A ^d  

^a BAYER PHARMA AG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Talima Therapeutics   (United States)

^d NEKTAR THERAPEUTICS   (United States)

Author keywords

aerosol; amikacin; aminoglycoside; chronic kidney disease; Gram negative pneumonia; mechanical ventilation; pharmacokinetics; renal failure

Indexed keywords

AMIKACIN; BAY 41 6551; UNCLASSIFIED DRUG;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; COUGHING; CREATININE BLOOD LEVEL; DEVICE SAFETY; DIALYSATE LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMODIALYSIS; HUMAN; JAW PAIN; KIDNEY CLEARANCE; KIDNEY FAILURE; LUNG FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; NAUSEA; NEBULIZATION; NEUROLOGIC DISEASE; OPEN STUDY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; RHINORRHEA; RISK FACTOR; SALIVATION; SIDE EFFECT; SINGLE DRUG DOSE; THIRST; THORAX PAIN; VOMITING; XEROSTOMIA;

ADULT; AEROSOLS; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 79961087178     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0859     Document Type: Article

References (26)

1. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, and Quinn JP: Antibiotic resistance among Gramnegative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-888. (Pubitemid 37430348)
2. American Thoracic Society, and Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated pneumonia. Am J Respir Crit Care Med. 2005;171: 388-416.
3. Mombelli G, Coppens L, Thys JP, and Klastersky J: Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob Agents Chemother. 1981;19:72-75. (Pubitemid 11132462)
4. Bedford Laboratories: Amikacin (amikacin) Prescribing Information. 2007.
5. Hammett-Stabler CA, and Johns T: Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem. 1998;44:1129-1140. (Pubitemid 28213161)
6. Dhand R: The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care. 2007;52:866-884.
7. Dhand R, and Sohal H: Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices. 2008;5:9-18.
8. Chastre J, Sanchez M, Corkery K, Fink JB, Luyt CE, and Niederman MS: NKTR-061 achieves safe serum concentrations after repeat dosing in intubated, mechanically ventilated patients with Gram-negative pneumonia: a pharmacokinetic study. American Thoracic Society International Conference 2007, 18-23 May 2007; San Francisco, CA, USA. Poster 720.
9. Chastre J, Corkery K, Wood C, Clavel M, Guntupalli K, Gribben D, and Luyt C: High epithelial lining fluid (ELF) concentrations of NKTR 061 (inhaled amikacin) BID achieved in pneumonic portions of lung. 28th International Symposium on Intensive Care and Emergency Medicine, 18-21 March 2008; Brussels, Belgium. Poster 463.
10. Corkery K, Gribben D, Fink J, Eldon M, and Niederman M: Evidence of high amikacin lung deposition in mechanically ventilated patients (MVP) with pneumonia and healthy subjects (HS) dosed using NKTR-061. American Thoracic Society International Conference 2008, 16-21 May 2008; Toronto, Canada. Poster 517.
11. Eldon M, Corkery K, Gribben D, Fink J, and Niederman M: NKTR-061 (inhaled amikacin) delivers high lung doses in mechanically ventilated patients (MVP) with pneumonia and healthy subjects (HS). 28th International Symposium on Intensive Care and Emergency Medicine, 18-21 March 2008; Brussels, Belgium. Poster A135.
12. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, and Chastre J: Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care. 2009;13:R200.
13. Santré C, Georges H, Jacquier JM, Leroy O, Beuscart C, Buguin D, and Beaucaire G: Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob Agents Chemother. 1995;39:264-267.
14. Regeur L, Colding H, Jensen H, and Kampmann JP: Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother. 1977;11: 214-218. (Pubitemid 8042469)
15. Madhavan T, Yaremchuk K, Levin N, Pohlod D, Burch K, Fisher E, Cox F, and Quinn EL: Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin. Antimicrob Agents Chemother. 1976;10:464-466.
16. Ahmed QA, and Niederman MS: Respiratory infection in the chronically critically ill patient. Ventilator-associated pneumonia and tracheobronchitis. Clin Chest Med. 2001;22:71-85. (Pubitemid 32290596)
17. Berman SJ, Johnson EW, Nakatsu C, Alkan M, Chen R, and LeDuc J: Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis. 2004;39:1747-1753. (Pubitemid 39657251)
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, and Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
19. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, and Ramsey BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219-226. (Pubitemid 34754166)
20. Al Amoud AI, Clark BJ, Assi KA, and Chrystyn H: Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers. Br J Clin Pharmacol. 2005;59:542-545. (Pubitemid 40632244)
21. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, and Quan J: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481-485. (Pubitemid 30647187)
22. Scheinberg P, and Shore E: A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127:1420-1426. (Pubitemid 46224309)
23. Luyt CE, Eldon M, Stass H, Gribben D, Corkery K, and Chastre J: Pharmacokinetics (PK) of BAY41-6551 in mechanically ventilated (MV) patients with Gram-negative pneumonia (GNP) and acute renal failure (ARF). American Thoracic Society International Conference 2009, 15-20 May 2009; San Diego, USA. Abstract 951113.
24. Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, and Mueller BA: Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008;3:355-361.
25. Dager WE, and King JH: Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother. 2006;40:9-14. (Pubitemid 43221467)
26. Niederman MS, Chastre J, Corkery K, Marcantonio A, Fink JB, Luyt CE, Sanchez M, and The Amikacin Study Group: NKTR-061 (inhaled amikacin) reduces intravenous antibiotic use in intubated mechanically ventilated patients during treatment of Gram-negative pneumonia. American Thoracic Society International Conference 2007, 18-23 May 2007; San Francisco, CA, USA. Poster 718.